Adverse Event Reporting—New FDA Report Puts Things in Perspective

Research published in the October 2008 issue of Pediatrics says that some of free prescription drug samples being distributed to pediatric patients may be unsafe. The researchers found that one in twenty American children received free drug samples in 2004—and that the most frequently distributed samples were unsafe to children. Four of the 15 most… Continue reading Adverse Event Reporting—New FDA Report Puts Things in Perspective

Chelation TACT Trial Announces that Enrollment Has Temporarily Ceased

The investigators and institutions that have been participating in the National Institutes of Health Trial to Assess Chelation Therapy (TACT) have temporarily and voluntarily suspended enrollment of new participants in the study. The lead TACT investigator, Gervasio Lamas, M.D., of the University of Miami’s Miller School of Medicine, received a complaint from an outside party… Continue reading Chelation TACT Trial Announces that Enrollment Has Temporarily Ceased

The FDA and Vitamin B-6

In recent issues, we have told you about Medicure Pharma’s so-called Citizens Petition to the FDA to ban any dietary supplements containing the natural and active form of vitamin B-6 called pyridoxal 5′-phosphate (P5P).  A reader has asked: what is the difference between pyridoxine, the most common form of B-6, and P5P? Most supplements contain… Continue reading The FDA and Vitamin B-6

FDA’s Stealth Attack on Chelation Therapy for Cardio-Vascular Disease

The Food and Drug Administration (FDA) recently released a Public Health Advisory on Edetate Disodium (EDTA).  The advisory reflects FDA’s current analysis of data available concerning this drug.  The advisory is meant to alert patients and healthcare professionals about EDTA.